DFX Intelligence

Data Factory

Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics

series b

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:4d8c8ba3-c014-44e4-86de-7db42986539c

Data as of Sep 13, 2026 (this record's last observation) from Sworn filings; Announcements; Limited partners. Page built Sep 19, 2026, 11:37 PM UTC and rebuilt at most every 15 minutes.

Relationships: 8
Dated events: 1
On other graphs: 1
Observed: Sep 13, 2026 to Sep 13, 2026
1 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Private Equityidentity

Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics

Portfolio company · cited

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Rounds: 1
Latest round: Series B 2026-03-26
Latest round amount: $89.0M
Total disclosed raised: $89.0Mderivedsum of disclosed round sizes only
Investors: 6
People: 0

Rounds

Announced	Round	Stage	Amount	Basis	Investors
Mar 26, 2026	Series B	Series b	$89.0M	disclosed	n/a

Investors

Investor	Class	Fund	Partner	Role	Attribution
Foresite Capital	Multi stage VC	n/a	Cindy Xiong	lead	Confirmed
Quan Capital Management, LLC	Institutional VC	n/a	n/a	participant	Unknown
HanKang Capital	Candidate VC	n/a	n/a	participant	Unknown
RA Capital Management, LP	Institutional VC	n/a	n/a	participant	Unknown
Lav	Candidate VC	n/a	n/a	lead	Unknown
Logos Capital	Candidate VC	n/a	n/a	participant	Unknown

Relationships

Invested in (8)

← LAVFirmround
Mar 26, 2026 to presentfactNews and newswire
← Quan CapitalFirmround
Mar 26, 2026 to presentfactNews and newswire
← HanKang CapitalFirmround
Mar 26, 2026 to presentfactNews and newswire
← RA Capital Management, LPFirmround
Mar 26, 2026 to presentfactNews and newswire
← Foresite CapitalFirmround
Mar 26, 2026 to presentfactNews and newswire
← DOYLESTOWNFirmround
Mar 26, 2026 to presentfactNews and newswire
← PaFirmround
Mar 26, 2026 to presentfactNews and newswire
← Logos CapitalFirmround
Mar 26, 2026 to presentfactNews and newswire

Dated events

Occurred
Mar 26, 2026
Round announced
Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics announced Series B of $89,000,000, led by LAV, Foresite Capital
News and newswireobserved 6 days ago
$89.0M

Provenance

Graph: Venture Capital
Canonical id: dfx:vc:4d8c8ba3-c014-44e4-86de-7db42986539c
First observed: Sep 13, 2026
Last observed: Sep 13, 2026 6 days ago
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics

series b

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:4d8c8ba3-c014-44e4-86de-7db42986539c

Data as of Sep 13, 2026 (this record's last observation) from Sworn filings; Announcements; Limited partners. Page built Sep 19, 2026, 11:37 PM UTC and rebuilt at most every 15 minutes.

Announced

Round

Stage

Amount

Basis

Investors

Mar 26, 2026

Series B

Series b

$89.0M

disclosed

n/a

Investor

Class

Fund

Partner

Role

Attribution

Foresite Capital

Multi stage VC

n/a

Cindy Xiong

lead

Confirmed

Quan Capital Management, LLC

Institutional VC

n/a

participant

Unknown

HanKang Capital

Candidate VC

n/a

participant

Unknown

RA Capital Management, LP

Institutional VC

n/a

participant

Unknown

Lav

Candidate VC

n/a

lead

Unknown

Logos Capital

Candidate VC

n/a

participant

Unknown